Gabapentin
Product Images NDC 45865-356

7 FDA label images from Medsource Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 45865-356). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medsource Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Equate (Equation)

Equate (Equation)
A formula panel showing the calculation for creatinine clearance (CLCr) with variables including age, weight, serum creatinine, and an adjustment factor for female patients. This text panel provides a pharmacokinetic calculation relevant to dosing considerations.*
FDA Label Image

Molecule (Molecule)

Molecule (Molecule)
Chemical structure of Gabapentin showing a cyclohexane ring with an amino group (H2N) and a carboxyl group (COOH) attached to the same carbon atom.*
FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
A line graph showing mean pain scores over an 8-week period comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks from baseline to week 8, and the y-axis shows mean pain scores from 0 to 10. The graph includes annotations for a 4-week dose titration period followed by a 4-week fixed dose period.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
Line graph showing mean pain scores over 7 weeks for placebo and two Gabapentin dosages (1800 mg/day and 2400 mg/day). The x-axis represents weeks, including a 3-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores ranging from 0 to 10. Gabapentin groups show decreased pain scores compared to placebo over time.*
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
A bar graph titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) treatment groups in two studies. The y-axis shows percentage responders from 0% to 100%. Study 1 and Study 2 results show higher responder rates for GBP 3600, 1800, and 2400 mg doses versus placebo, with statistical significance indicated by ** p < 0.01 and *** p < 0.001.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
A scatter plot comparing differences (%) by daily dose (mg) for three studies labeled a, b, and c. The x-axis shows daily dose ranging from 600 to 1800 mg, and the y-axis shows difference percentages from 2% to 22%. Data points for each study are marked with different colors and shapes, illustrating variations across the doses.*
FDA Label Image

Pdp (356 60)

Pdp (356 60)
Gabapentin Tablets 600mg label from Medsource Pharmaceuticals. The bottle contains 60 white, oval, scored tablets, generic for Neurontin. The label includes NDC 45865-0356-60, manufacturer Glenmark Generics Inc., and warnings about dizziness, drowsiness, and avoiding alcohol. Directions to take tablets daily are partially visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.